BERLIN and SEATTLE, Oct. 16, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported positive final results from its prognostic prostate cancer study.